Role of Bumetanide in Treatment of Autism

Sherief Abd-Elsalam

Status and phase: Enrolling; Phase 3

Conditions: Autism

Treatments: Drug: Bumetanide; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04766177

autism

Details and patient eligibility

About

Role of bumetanide in Autism

Full description

Role of Bumetanide in Treatment of Autism spectrum disorder in children

Enrollment: 80 estimated patients

Sex: All

Ages: 3 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. All patients with ASD diagnosed by CARS rating Scale⩾30.
2. Age of patients range between (3-12) years.

Exclusion criteria

• Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

80 participants in 2 patient groups, including a placebo group

bumetanide group

Experimental group

Description:

Bumetanide a dose of 0.5 mg twice per day

Treatment:

Drug: Bumetanide

Placebo

Placebo Comparator group

Description:

Placebo twice daily

Treatment:

Drug: Placebo